Cosciens Biopharma Financials
This page shows Cosciens Biopharma (CSCI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Cash burn, not product revenue, is the dominant mechanic: liquidity still looks workable even as the equity base thins.
FY2025 shows losses that translate into real cash use: operating cash flow was-$8.5M against net income of-$10.4M , so weak earnings are not being masked by working-capital timing. At the same time, the balance sheet absorbed the strain: equity ended at$3.8M after a sharp decline from the prior year and assets fell to$21.4M , meaning liquidity was maintained on a much smaller capital base.
This is not capital-intensive in the usual sense: capital spending was only
Near-term obligations are not the immediate pinch point. A current ratio above 3x and cash of
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Cosciens Biopharma's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Cosciens Biopharma passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Cosciens Biopharma generates $0.82 in operating cash flow (-$8.5M OCF vs -$10.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Cosciens Biopharma generated $7.5M in revenue in fiscal year 2025. This represents a decrease of 21.8% from the prior year.
Cosciens Biopharma reported -$10.4M in net income in fiscal year 2025. This represents an increase of 32.3% from the prior year.
Cash & Balance Sheet
Cosciens Biopharma generated -$9.2M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 41.6% from the prior year.
Cosciens Biopharma held $7.3M in cash against $1.9M in long-term debt as of fiscal year 2025.
Cosciens Biopharma had 3M shares outstanding in fiscal year 2025. This represents an increase of 1.4% from the prior year.
Margins & Returns
Cosciens Biopharma's net profit margin was -138.1% in fiscal year 2025, showing the share of revenue converted to profit. This is up 21.5 percentage points from the prior year.
Cosciens Biopharma's ROE was -269.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 153.3 percentage points from the prior year.
Capital Allocation
Cosciens Biopharma invested $706K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 39.2% from the prior year.
CSCI Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.8M+19.1% | $1.5M-46.1% | $2.7M+83.3% | $1.5M-54.8% | $3.3M+77.6% | $1.9M-19.9% | $2.3M+13.6% | $2.1M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Income | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Interest Expense | $17K-96.6% | $504K+245.2% | -$347K-813.2% | -$38K+98.3% | -$2.2M-616.2% | $426K-77.1% | $1.9M+185800.0% | $1K |
| Income Tax | N/A | N/A | $1K | N/A | $1.1M+1066.1% | -$112K+76.4% | -$474K-15.0% | -$412K |
| Net Income | -$2.2M-20.0% | -$1.8M+32.7% | -$2.7M+26.1% | -$3.7M+45.7% | -$6.7M-17.0% | -$5.8M-304.7% | -$1.4M-1.5% | -$1.4M |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
CSCI Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $21.4M-10.2% | $23.9M-13.4% | $27.6M-11.5% | $31.1M-11.2% | $35.1M-19.9% | $43.8M-12.5% | $50.0M+57.4% | $31.8M |
| Current Assets | $11.5M-16.9% | $13.8M-16.2% | $16.5M-18.9% | $20.4M-15.1% | $24.0M-15.0% | $28.2M-15.0% | $33.2M+6.5% | $31.2M |
| Cash & Equivalents | $7.3M-14.3% | $8.5M-8.7% | $9.3M-32.2% | $13.8M-16.1% | $16.4M-18.0% | $20.0M-28.1% | $27.8M+693.0% | $3.5M |
| Inventory | $1.3M-25.7% | $1.8M-3.4% | $1.8M-25.8% | $2.5M-8.8% | $2.7M-18.6% | $3.3M+8.2% | $3.1M+4673.4% | $64K |
| Accounts Receivable | $1.3M-21.4% | $1.6M-42.3% | $2.8M+49.7% | $1.9M-21.1% | $2.4M+24.6% | $1.9M+52.8% | $1.2M+551.6% | $190K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $17.6M-6.3% | $18.8M-8.2% | $20.5M-2.6% | $21.0M-4.2% | $21.9M-7.8% | $23.8M-0.3% | $23.8M+26.5% | $18.8M |
| Current Liabilities | $3.6M-9.3% | $4.0M-28.0% | $5.5M-21.6% | $7.1M-2.3% | $7.2M-11.6% | $8.2M-17.5% | $9.9M+88.5% | $5.3M |
| Long-Term Debt | $1.9M-1.3% | $2.0M-4.4% | $2.0M+3.9% | $2.0M-3.2% | $2.0M+68.4% | $1.2M-5.4% | $1.3M+1500.0% | $80K |
| Total Equity | $3.8M-24.4% | $5.1M-28.4% | $7.1M-30.0% | $10.1M-22.9% | $13.2M-34.2% | $20.0M-23.7% | $26.2M+36.7% | $19.2M |
| Retained Earnings | -$20.5M-7.7% | -$19.0M-10.6% | -$17.2M-17.6% | -$14.7M-21.0% | -$12.1M-134.8% | -$5.2M-436.5% | $1.5M+100.4% | -$375.3M |
CSCI Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.5M-117.5% | -$676K+84.8% | -$4.4M-136.5% | -$1.9M+37.3% | -$3.0M+61.4% | -$7.8M-460.0% | -$1.4M+41.6% | -$2.4M |
| Capital Expenditures | $46K+1250.0% | -$4K-108.2% | $49K-92.0% | $615K+99.0% | $309K+135.9% | $131K-16.6% | $157K-72.2% | $564K |
| Free Cash Flow | -$1.5M-122.9% | -$680K+84.9% | -$4.5M-80.2% | -$2.5M+24.6% | -$3.3M+58.2% | -$7.9M-411.6% | -$1.5M+47.5% | -$2.9M |
| Investing Cash Flow | $201K+4925.0% | $4K+108.3% | -$48K+92.2% | -$615K-94.6% | -$316K-480.7% | $83K-99.7% | $25.9M+4688.7% | -$564K |
| Financing Cash Flow | -$15K+82.4% | -$85K+20.6% | -$107K+46.5% | -$200K+1.0% | -$202K-7.4% | -$188K-49.2% | -$126K-34.0% | -$94K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
CSCI Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | -123.6%-1.0pp | -122.7%-24.4pp | -98.3%+145.4pp | -243.7%-41.1pp | -202.6%+105.0pp | -307.6%-246.7pp | -60.9%+7.3pp | -68.1% |
| Return on Equity | -56.8%-21.0pp | -35.8%+2.3pp | -38.1%-2.0pp | -36.0%+15.1pp | -51.1%-22.4pp | -28.7%-23.3pp | -5.4%+1.9pp | -7.3% |
| Return on Assets | -10.2%-2.6pp | -7.6%+2.2pp | -9.8%+1.9pp | -11.7%+7.4pp | -19.2%-6.0pp | -13.2%-10.3pp | -2.8%+1.6pp | -4.4% |
| Current Ratio | 3.18-0.3 | 3.47+0.5 | 2.98+0.1 | 2.88-0.4 | 3.32-0.1 | 3.46+0.1 | 3.35-2.6 | 5.94 |
| Debt-to-Equity | 0.50+0.1 | 0.39+0.1 | 0.29+0.1 | 0.19+0.0 | 0.15+0.1 | 0.06+0.0 | 0.05+0.0 | 0.00 |
| FCF Margin | -85.8%-40.0pp | -45.9%+117.7pp | -163.5%+2.8pp | -166.3%-66.8pp | -99.6%+323.2pp | -422.8%-356.6pp | -66.1%+77.0pp | -143.1% |
Similar Companies
Frequently Asked Questions
What is Cosciens Biopharma's annual revenue?
Cosciens Biopharma (CSCI) reported $7.5M in total revenue for fiscal year 2025. This represents a -21.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Cosciens Biopharma's revenue growing?
Cosciens Biopharma (CSCI) revenue declined by 21.8% year-over-year, from $9.6M to $7.5M in fiscal year 2025.
Is Cosciens Biopharma profitable?
No, Cosciens Biopharma (CSCI) reported a net income of -$10.4M in fiscal year 2025, with a net profit margin of -138.1%.
How much debt does Cosciens Biopharma have?
As of fiscal year 2025, Cosciens Biopharma (CSCI) had $7.3M in cash and equivalents against $1.9M in long-term debt.
What is Cosciens Biopharma's net profit margin?
Cosciens Biopharma (CSCI) had a net profit margin of -138.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Cosciens Biopharma's return on equity (ROE)?
Cosciens Biopharma (CSCI) has a return on equity of -269.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Cosciens Biopharma's free cash flow?
Cosciens Biopharma (CSCI) generated -$9.2M in free cash flow during fiscal year 2025. This represents a 41.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Cosciens Biopharma's operating cash flow?
Cosciens Biopharma (CSCI) generated -$8.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Cosciens Biopharma's total assets?
Cosciens Biopharma (CSCI) had $21.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Cosciens Biopharma's capital expenditures?
Cosciens Biopharma (CSCI) invested $706K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Cosciens Biopharma's current ratio?
Cosciens Biopharma (CSCI) had a current ratio of 3.18 as of fiscal year 2025, which is generally considered healthy.
What is Cosciens Biopharma's debt-to-equity ratio?
Cosciens Biopharma (CSCI) had a debt-to-equity ratio of 0.50 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Cosciens Biopharma's return on assets (ROA)?
Cosciens Biopharma (CSCI) had a return on assets of -48.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Cosciens Biopharma's cash runway?
Based on fiscal year 2025 data, Cosciens Biopharma (CSCI) had $7.3M in cash against an annual operating cash burn of $8.5M. This gives an estimated cash runway of approximately 10 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Cosciens Biopharma's Piotroski F-Score?
Cosciens Biopharma (CSCI) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Cosciens Biopharma's earnings high quality?
Cosciens Biopharma (CSCI) has an earnings quality ratio of 0.82x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Cosciens Biopharma?
Cosciens Biopharma (CSCI) scores 40 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.